Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising

Everest Medicines Announces CTA Approval by China NMPA for Phase 3 Trial of Sacituzumab Govitecan-Hziy for Metastatic Urothelial Cancer

prnasiaJanuary 07, 2021

Tag: Everest Medicines , urothelial cancer , sacituzumab govitecan-hziy

PharmaSources Customer Service